Key Takeaways
ADMA Biologics (NASDAQ: ADMA) slashed its full-year 2026 revenue and profit guidance, citing intense competition and pricing pressure that has hammered sales of its Bivigam immune globulin therapy and sent its stock tumbling.
"Increased competition, elevated channel inventories and aggressive pricing activity in standard immunoglobulin products created temporary pressure," the company stated, explaining the guidance cut. The biopharmaceutical firm markets plasma-derived biologics for immune deficiencies and infectious diseases.
The company now expects 2026 revenue to be in a range of $530 million to $560 million, a sharp reduction from its previous forecast of exceeding $635 million. Adjusted net income guidance was also lowered to a range of $170 million to $200 million, down from prior expectations of more than $255 million. The revision follows a 54% year-over-year decline in first-quarter sales for Bivigam.
Shares of ADMA have plunged 21.8% over the past month and are down more than 53% year-to-date following the announcement. The guidance cut and subsequent downward revisions in earnings estimates have earned the company a Zacks Rank of #5 (Strong Sell).
Despite the steep sell-off and market headwinds, some institutional investors see an opportunity. A May 15 filing revealed that B Group Inc. purchased an additional 750,000 shares of ADMA. The stock now constitutes over 21% of the fund's reported assets under management, signaling strong conviction from at least one large holder.
The bull case appears centered on ADMA's other products. While Bivigam sales faltered, the company's lead product, Asceniv, saw revenues jump 28% year-over-year to $97.5 million. This growth helped keep total first-quarter revenue nearly flat at $114.5 million and allowed the company to post a 22% increase in adjusted net income to $40.7 million while generating $58 million in operating cash flow.
ADMA operates in a competitive plasma-derived therapies market against larger players like Grifols, Takeda, and CSL Group. To improve its footing, the company recently launched a new distribution agreement with McKesson Specialty, which it expects will expand market reach and improve ordering consistency.
The sharp guidance revision highlights the competitive risks facing Bivigam, but Asceniv's continued growth and a major investor's increased stake present a conflicting picture. Investors will be closely watching second-quarter results to see if management's assertion of a revenue trough in the first quarter proves to be accurate.
This article is for informational purposes only and does not constitute investment advice.
